<DOC>
	<DOCNO>NCT01652547</DOCNO>
	<brief_summary>This study evaluate preliminary safety , pharmacokinetics , anti-tumor activity pasireotide s.c. patient metastatic melanoma metastatic Merkel cell carcinoma . The study consist three phase : screening , intra-patient dose-escalation , follow-up phase . In screen phase patient inform aspect study sign inform consent form screen study eligibility . During intra-patient dose escalation phase , 18 patient treat pasireotide s.c. 300 μg t.i.d . 2 week . If unacceptable AEs , define drug-related clinically meaningful , uncontrolled grade 3 grade 4 toxicity , patient dose escalated 600 μg t.i.d . 2 week , 900 μg t.i.d . 2 week 1200 μg 2 week provide unacceptable AEs . Each patient dose escalation phase maximum 8 week . At end intra-patient dose escalation phase , patient allow switch 80 mg pasireotide LAR i.m . q 28 ( low dose case toxicity ) additional 6 month disease progression , unacceptable AEs , patient withdraws consent . In addition , patient keep pasireotide s.c. t.i.d . treatment ( dose end 8-week dose escalation phase ) first 2 week LAR follow-up phase , except day receive first LAR dose anticipate initial burst drug release .</brief_summary>
	<brief_title>A Phase I , Exploratory , Intra-patient Dose Escalation Study Investigate Preliminary Safety , Pharmacokinetics , Anti-tumor Activity Pasireotide ( SOM230 ) s.c.Followed Pasireotide LAR Patients With Metastaticmelanoma Metastatic Merkel Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must histologically cytologically confirm unresectable ( stage III ) and/or metastatic ( stage IV ) melanoma unresectable and/or metastatic Merkel cell carcinoma . 2 . Melanoma patient mutation BRAF NRAS gene 3 . Patients lesion biopsied , addition measurable nonmeasurable metastatic lesion 1 lesion suitable 18FDGPET scan CT/MRI . 4 . ECOG Performance Status 0 1 5 . Presence measurable nonmeasurable disease accord RECIST 1.0 6 . Adequate organ function : adequate bone marrow function ( WBC ≥ 2.5 x 109/L , ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 9 g/dL ) ; serum creatinine ≤ 1.5 mg/dL estimate glomerular filtration rate ( eGFR ) &gt; 40 ml/min/m2 ; serum lipase ≤ 1.5 ULN Exclusion criterion : 1 . Patient primary uveal melanoma 2 . Patients symptomatic CNS metastasis neurologically unstable require increase dos steroid control CNS disease 3 . Patient previously treat somatostatin analogue radiolabeled somatostatin analogs patient know hypersensitivity somatostatin analogs component pasireotide s.c. i.m . formulation excipients 4 . Patients standard treatment available indicated due rapidly progressive aggressive disease 5 . Patients receive 3 prior line systemic therapy treatment disease . 6 . Patients receive antineoplastic therapy within 4 week prior baseline 7 . Patients receive investigational drug within 1 month prior baseline 8 . Patients undergone major surgery/surgical therapy cause within 1 month prior baseline . Patients must recover treatment stable clinical condition enter study 9 . Patients receive prior radiation therapy ≤ 4 week , limited field radiation ≤ 2 week , prior baseline side effect therapy resolve ≤ grade 1 . 10 . Patients unwilling perform repeat biopsy 11 . Patients know gallbladder bile duct disease , acute chronic pancreatitis ( patient asymptomatic cholelithiasis asymptomatic bile duct dilation include ) 12 . Patients abnormal coagulation ( PT PTT elevate 30 % normal limit ) 13 . Patients continuous anticoagulation therapy . Patients anticoagulant therapy must complete washout period least 10 day prior baseline confirm normal coagulation parameter study inclusion 14 . Patients biochemically euthyroid 15 . Patients known history hypothyroidism eligible adequate stable replacement thyroid hormone therapy least 3 month prior baseline 16 . Patients QTrelated exclusion criterion 17 . Baseline QTcF &gt; 450 ms History syncope family history idiopathic sudden death Known history prolong QT syndrome Sustained clinically significant cardiac arrhythmia Patients risk factor torsades de pointes uncorrected hypokalemia , uncorrected hypomagnesemia , clinically relevant cardiac failure ( NYHA class III IV ) , clinically significant/symptomatic bradycardia highgrade AV block Concomitant medication know prolong QT interval Known concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes mellitus Parkinson 's disease ) , HIV , liver cirrhosis , uncontrolled hypothyroidism cardiac failure Patients unstable angina , sustain ventricular tachycardia , ventricular fibrillation , high grade ( NOT advanced ! ) heart block history acute myocardial infarction less one year prior baseline 18 . Patients follow severe and/or uncontrolled medical condition : Uncontrolled diabetes define HbA1c &gt; 8 % despite adequate therapy Patients presence active suspect acute chronic uncontrolled infection history immunodeficiency , include positive HIV test result ( ELISA Western blot ) Liver disease history liver disease cirrhosis , decompensated liver disease , chronic active hepatitis B C chronic persistent hepatitis Lifethreatening autoimmune ischemic disorder 19 . Patients history another primary malignancy , exception locally excise nonmelanoma skin cancer carcinoma situ uterine cervix . Patients evidence disease another primary cancer 3 year allow participate study 20 . Pregnant nursing ( lactate ) woman 21 . Women childbearing potential 22 . Patients baseline ALT AST &gt; 3 x ULN baseline total bilirubin &gt; 1.5x ULN 23 . Patients presence Hepatitis B surface antigen ( HbsAg ) presence Hepatitis C antibody test ( antiHCV ) 24 . History , current alcohol misuse/abuse within past 12 month prior visit 1 ( baseline ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Merkel cell carcinoma</keyword>
	<keyword>Metastatic skin cancer</keyword>
</DOC>